3상완료

Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects

연구 개요

This is an 8-week, randomized, double-blind Phase 3, multicentre study to determine the optimal dose of AZM and AML in combination therapy and to compare efficacy and tolerability of the combined therapy to each of the monotherapy in essential hypertensive subjects who are not adequately controlled on AZM and AML monotherapy.

스폰서: 리드: 셀트리온
적응증: Essential Hypertension
중재: AZM X mg + AML Y mg, AZM X mg + AML Y' mg, AZM X' mg + AML Y mg, AZM X' mg + AML Y' mg, AZM X mg, AZM X' mg, AML Y mg, AML Y' mg
목표 등록: 890명
시작일: 2022-07-08
완료(예정): 2024-07-19
등록번호: NCT05385770 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.